Calliditas riding high after positive Phase III data for budesonide

Swedish rare disease company Calliditas Therapeutics (Nasdaq: CALT) has announced positive Phase III results for Tarpeyo (budesonide) in primary IgA nephropathy (IgAN).

Outlining the significance of the readout, Professor Jonathan Barratt of Leicester University said the data “demonstrate that the approach offers patients a truly disease modifying treatment.”

He added: “Importantly, budesonide was well tolerated and…has cemented its place as a key treatment option for patients with IgA nephropathy at risk of progressive kidney function loss.”